Efinopegdutide

DRUG8 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Fatty Liver, NonalcoholicHealthyHepatic ImpairmentLiver DiseaseMetabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-associated SteatohepatitisMetabolic Dysfunction-associated Steatotic Liver Disease

Phase 1

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

CompletedNCT06052566

Merck Sharp & Dohme LLCHepatic Impairment, Non-alcoholic Steatohepatitis

Start: 2023-11-21End: 2024-12-05Updated: 2025-10-22

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

CompletedNCT06701305

Merck Sharp & Dohme LLCHealthy

Start: 2024-06-13End: 2025-02-18Updated: 2025-02-26

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

CompletedNCT06836037

Merck Sharp & Dohme LLCHealthy

Start: 2022-09-05End: 2023-02-02Updated: 2025-02-21

Phase 2

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

CompletedNCT05877547

Merck Sharp & Dohme LLCFatty Liver, Nonalcoholic, NAFLD, Non-alcoholic Fatty Liver Disease +2

Start: 2023-06-23End: 2025-12-29Updated: 2026-01-12

A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis

CompletedCTIS2022-502647-35-00

Merck Sharp & Dohme LLCNon-alcoholic steatohepatitis

Start: 2023-09-01End: 2025-12-29Target: 67Updated: 2025-12-10

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Active, not recruitingNCT06465186

Merck Sharp & Dohme LLCMetabolic Dysfunction-associated Steatohepatitis, Metabolic Dysfunction-associated Steatotic Liver Disease, NAFLD +2

Start: 2024-07-12End: 2026-08-06Target: 80Updated: 2026-03-02

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

CompletedNCT06482112

Merck Sharp & Dohme LLCLiver Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease +1

Start: 2024-07-29End: 2025-06-27Updated: 2026-06-01

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis

Active, not recruitingCTIS2024-510923-20-00

Merck Sharp & Dohme LLCMetabolic Dysfunction-Associated Steatohepatitis

Start: 2024-09-16Target: 24Updated: 2025-10-24